

**Registered Office:**

Plot No. PF21 & PF-22/A, Charal Industrial Estate,  
Sanand GIDC-II, Sanand,  
Ahmedabad- 382110, Gujarat.

**CIN.: L24230GJ2015PLC085451**

**Date:** December 09, 2025

To,  
**The Manager-Listing**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Mumbai – 400051

**Respected Sir/Ma'am,**

**Sub: Update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Receipt of Purchase Order.**

***Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)***

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that our Company has received a **Purchase Order** from **Cadila Pharmaceuticals Limited** dated December 08, 2025, via mail on December 09, 2025 amounting to **Rs. 1,73,55,534/-** i.e. (Rupees One Crore Seventy-Three Lakh Fifty-Five Thousand Five Hundred Thirty-Four Only) exclusive of GST for supply of Levozet M Tablet (Montelukast Sodium & Levocetirizine Hydrochloride).

This order presents a significant opportunity for our company to further demonstrate its manufacturing capabilities and to strengthen our relationship with our customers, thereby contributing positively to its business growth prospects.

***Further Details with respect to said order as required under regulation 30 of listing regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 is enclosed as Annexure A.***

You are requested to kindly note the same.

Thanking you.

Yours faithfully,  
**For, Sotac Pharmaceuticals Limited**

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**

**Place:** Ahmedabad

**Encl:** A/a-

**Registered Office:**

Plot No. PF21 & PF-22/A, Charal Industrial Estate,  
Sanand GIDC-II, Sanand,  
Ahmedabad- 382110, Gujarat.

**CIN.: L24230GJ2015PLC085451****Annexure A**

*Details with respect to said order as required under regulation 30 of listing regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 are attached herewith:*

Sr. No.	Particulars	Details
1.	Name of the entity awarding the order(s)/contract(s);	Cadila Pharmaceuticals Limited
2.	Whether order(s) / contract(s) have been awarded by domestic/ <del>international entity</del> ;	Domestic
3.	Nature of Contract, significant terms and conditions of order awarded, broad commercial consideration or size of the order;	<p>The Company has received a purchase order from Cadila Pharmaceuticals Limited for supply of pharmaceutical product – Levozet M Tablet (Montelukast Sodium &amp; Levocetirizine Hydrochloride).</p> <p>The total order value is Rs. 1,73,55,534/- (Rupees One Crore Seventy-Three Lakh Fifty-Five Thousand Five Hundred Thirty-Four Only) exclusive of GST.</p> <p><b><u>Significant Terms:</u></b></p> <p><b>Payment Terms:</b> 45 Days (credit)</p> <p><b>Terms of Dispatch:</b> Ex-work</p>
4.	Time period by which the order(s)/contract(s) is to be executed;	<p><b><u>Delivery Schedule:</u></b></p> <p>Staggered supplies between January 18, 2026 and January 30, 2026.</p>
5.	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof;	No
6.	Whether the order(s)/contract(s) would fall within related party transactions? If yes, whether the same is done at “arm’s length”.	No

**For, Sotac Pharmaceuticals Limited**

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**

**Place: Ahmedabad**